Διείσδυση γενοσήμων στην αγορά φαρμάκου, οφέλη και εξοικονομήσεις για το σύστημα υγείας. Εμπειρική μελέτη σκευασμάτων εσομεπραζόλης σε 5 ευρωπαϊκές αγορές
Market penetration of generics, benefits and savings for the health system. The example of Esomeprazol study in 5 European markets
KeywordsΓενόσημα φάρμακα ; Σύστημα υγείας ; Πατέντες ; Εξοικονόμηση πόρων ; Μερίδιο αγοράς ; Τιμές φαρμάκων ; Κόστος ημερήσιας θεραπείας ; Health system ; Medicines ; Generics ; Originators ; Patent ; Loss of exclusivity ; Patent expiration ; Savings ; Market share ; Generics policy ; Prices of medicines ; Cost of daily treatment ; Genericisation ; Generics paradox
The global challenges from the recent financial crisis are many and are threatening most of Europe’s health systems. The loss of GDP has had a profound impact on the viability of most European health systems and governments across Europe are implementing health policies which target the cost of pharmaceutical spending. Most European markets are introducing generics very early after patent expiration in an effort to maximize the savings produced by the cheapest clinical alternatives. The generics policies implemented by most European countries are supportive to the wide use of generics instead of off-patent medicines and the incentives used by the stakeholders in order to achieve great market shares for generics are numerous. Greece on the other hand has been defined as one of the European countries with the lowest market share of generics in comparison. Lack of political will and the implementation of the wrong policy mix along with low level of acceptance for generics are the characteristics of the current market state. This study used data to examine the entry point for esomeprazole generics after patent expiration in 5 European markets along with the following developments in market shares, prices and cost of daily treatment for generics and originators. The results from this study agree with the findings published in numerous reports which state that the loss of potential savings from the inadequate use of generics in Greece, is something that the country cannot afford anymore therefore the government needs to immediately modify the policy mix currently in use.